LRRK2 and Parkinson disease: Despite the effects directly obtained in OPCs in vitro, LRRK2 inhibition with compound 4 may reflect the anti‐inflammatory effect that is previously known from different scenarios and very recently suggested in patients with Parkinson's disease, too.52, 53